Abstract:In the last decade, the opioid overdose epidemic has been exacerbated by the emerging drug of abuse, xylazine. This veterinary anesthetic, an alpha-2 agonist, not only potentiates the fatal effects of opioids but also causes toxic endothelial effects. This review aims to assess the impact of xylazine use and overdoses within the context of the opioid crisis as a public health issue. The research used data from scientific publications, state health reports, and analyses from the Institute of Forensic Sciences of Puerto Rico. The databases PubMed, Google Scholar, and Scopus were searched for relevant publications. The search strategy employed two groups of terms: the drug of interest (xylazine) and types of exposure (drug use, overdose, substance abuse, etc.). The initial search in PubMed was then extrapolated, and the search terms were adjusted for appropriate database syntax. According to the most recent publications and CDC data in the USA, approximately 95% of fentanyl overdose cases involve xylazine, while the other 5% of overdose cases are attributed solely to xylazine, predominantly administered intravenously. In the last four years, more than 4,000 overdose deaths have been related to xylazine use; the northeastern United States had reported the most significant number of deaths. This number changes daily as reanalysis results and new data are published. Less than 50% of states perform tests for xylazine detection or maintain statistical monitoring of overdoses related to this drug. The absence of testing impedes emergency room physicians from making accurate diagnoses, increasing the likelihood of fatal overdoses. This review highlights five major concerns: (1) The recognition of intoxication as a primary concern and the unavailability of alpha-2 antagonists for treatment. (2) The challenges in the clinical setting linked to xylazine abuse and its co-administration with substances like fentanyl and its analogs. (3) The necessity for robust government statistical resources for the unification and dissemination of critical overdose and emerging drug abuse detection information. (4) The need for effective rehabilitation programs, including psychosocial support and treatment interventions, to respond to this public health crisis. (5) The urgency for further research to understand the prevalence, toxic effects of chronic or acute use, and the clinical implications in xylazine users, including the development of alpha-2 antagonists for treatment. We conclude that addressing these concerns is crucial to working with the xylazine abuse situation.

Public health impact and harm reduction implications of xylazine-involved overdoses: a narrative review

Xylazine Abuse, The Growing Risk: A Review of Its Effects, Upsurge Use and Associated Fatalities in the USA and Puerto Rico.

Xylazine in the Opioid Epidemic: A Systematic Review of Case Reports and Clinical Implications

Xylazine Adulteration of the Heroin-Fentanyl Drug Supply : A Narrative Review

Xylazine poisoning: a systematic review

Xylazine in the Unregulated Drug Market: An Integrative Review of Its Prevalence, Health Impacts, and Detection and Intervention Challenges in the United States

Xylazine Spreads Across the US: A Growing Component of the Increasingly Synthetic and Polysubstance Overdose Crisis

The New Stealth Drug on the Street: A Narrative Review of Xylazine as a Street Drug

Reducing the harms of xylazine: clinical approaches, research deficits, and public health context

Xylazine in Overdose Deaths and Forensic Drug Reports in US States, 2019-2022

Opioid overdoses involving xylazine in emergency department patients: a multicenter study

Drug Overdose Deaths Involving Xylazine, United States, 2018–2021

National Institute on Drug Abuse Clinical Trials Network Meeting Report: Managing Patients Exposed to Xylazine-Adulterated Opioids in Emergency, Hospital and Addiction Care Settings

Xylazine: A Drug Adulterant of Clinical Concern

Implications of xylazine exposure in pregnancy: a narrative review

Analytical methods for the determination of xylazine in pharmaceutical, clinical and forensic matrices – A review

Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010–2019

Xylazine effects on opioid-induced brain hypoxia

Providers' knowledge and perception of xylazine in the unregulated drug supply: a sequential explanatory mixed-methods study

Xylazine's Impacts on the Community in Philadelphia: Perspectives of People Who Use Opioids and Harm Reduction Workers

Illicitly Manufactured Fentanyl–Involved Overdose Deaths with Detected Xylazine — United States, January 2019–June 2022